GH Research (GHRS) Cash from Operations (2020 - 2025)
GH Research's (GHRS) quarterly Cash from Operations came in at 12330000.0 in Q4 2025, down 18.04% year-on-year from 15043118.43 in Q4 2024, and up 9.88% quarter-over-quarter from 13682000.0 in Q3 2025.
GH Research (GHRS) Cash from Operations (2020 - 2025) Analysis & Trends
GH Research's Cash from Operations history runs 6 years deep, the most recent figure standing at 12330000.0 for Q4 2025.
- On a quarterly basis, Cash from Operations fell 18.04% year-over-year to 12330000.0 in Q4 2025; TTM through Dec 2025 was 43552000.0, a 3.0% decrease from a year earlier, with the FY2025 full-year figure at 43552000.0, down 3.0% from the prior year.
- Cash from Operations advanced to 12330000.0 in Q4 2025 per GHRS's latest filing, from 13682000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1087000.0 in Q1 2021 and bottomed at 13682000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 8770000.0 (2025), against an average of 8214050.0.
- Across the five-year window, Cash from Operations slumped 11864.94% in 2021 and increased 12.68% in 2022, its largest moves.
- Year by year, Cash from Operations stood at 3749000.0 in 2021, then sank by 83.17% to 6867000.0 in 2022, then plunged by 70.67% to 11720000.0 in 2023, then gained by 10.87% to 10446000.0 in 2024, then retreated by 18.04% to 12330000.0 in 2025.
- Per Business Quant, the three latest GHRS Cash from Operations figures stand at 12330000.0 (Q4 2025), 13682000.0 (Q3 2025), and 8967000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.17 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | -12.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.33 Mn |
| Dec 31, 2025 | -12.33 Mn |
| Sep 30, 2025 | -13.68 Mn |
| Sep 30, 2025 | -13.68 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Dec 31, 2024 | -10.45 Mn |
| Dec 31, 2024 | -10.45 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -9.94 Mn |
| Jun 30, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Dec 31, 2023 | -11.72 Mn |
| Dec 31, 2023 | -11.72 Mn |
| Sep 30, 2023 | -10.34 Mn |
| Sep 30, 2023 | -10.34 Mn |